Prokaryotic type II CRISPR-Cas systems can be adapted to enable targeted
genome modifications across a range of eukaryotes.1–7. Here we engineer this system to enable RNA-guided genome
regulation in human cells by tethering transcriptional activation domains either
directly to a nuclease-null Cas9 protein or to an aptamer-modified single guide
RNA (sgRNA). Using this functionality we developed a novel transcriptional
activation–based assay to determine the landscape of off-target binding
of sgRNA:Cas9 complexes and compared it with the off-target activity of
transcription activator–like (TAL) effector proteins8, 9.
Our results reveal that specificity profiles are sgRNA dependent, and that
sgRNA:Cas9 complexes and 18-mer TAL effector proteins can potentially tolerate
1–3 and 1–2 target mismatches, respectively. By engineering a
requirement for cooperativity through offset nicking for genome editing or
through multiple synergistic sgRNAs for robust transcriptional activation, we
suggest methods to mitigate off-target phenomena. Our results expand the
versatility of the sgRNA:Cas9 tool and highlight the critical need to engineer
improved specificity.
Digital information is accumulating at an astounding rate, straining our ability to store and archive it. DNA is among the most dense and stable information media known. The development of new technologies in both DNA synthesis and sequencing make DNA an increasingly feasible digital storage medium. We developed a strategy to encode arbitrary digital information in DNA, wrote a 5.27-megabit book using DNA microchips, and read the book by using next-generation DNA sequencing.
Most amino acids are encoded by multiple codons, and codon choice has strong effects on protein expression. Rare codons are enriched at the N terminus of genes in most organisms, although the causes and effects of this bias are unclear. Here, we measure expression from >14,000 synthetic reporters in Escherichia coli and show that using N-terminal rare codons instead of common ones increases expression by ~14-fold (median 4-fold). We quantify how individual N-terminal codons affect expression and show that these effects shape the sequence of natural genes. Finally, we demonstrate that reduced RNA structure and not codon rarity itself is responsible for expression increases. Our observations resolve controversies over the roles of N-terminal codon bias and suggest a straightforward method for optimizing heterologous gene expression in bacteria.
The ability to direct functional domains to specific DNA sequences is a long sought-after goal for studying and engineering biological processes. Transcription activator like effectors (TALEs) from Xanthomonas sp. present a promising platform for designing sequence-specific DNA binding proteins. Here we describe a robust and rapid method for overcoming the difficulty of constructing TALE repeat domains. We synthesized 17 designer TALEs (dTALEs) that are customized to recognize specific DNA binding sites, and demonstrate that dTALEs can specifically modulate transcription of endogenous genes (Sox2 and Klf4) from the native genome in human cells. dTALEs provide a designable DNA targeting platform for the interrogation and engineering of biological systems.
For over 60 years, the synthetic production of new DNA sequences has helped researchers understand and engineer biology. Here we summarize methods and caveats for the de novo synthesis of DNA, with particular emphasis on recent technologies that allow for large-scale and low-cost production. In addition, we discuss emerging applications enabled by large-scale de novo DNA constructs, as well as the challenges and opportunities that lie ahead.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.